secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcutis Biotherapeutics, Inc. (ARQT)
CIK:        0001787306
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001787306-23-000022
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcutis Q4 2022 net loss $72M; ZORYVE revenue $3M in first full quarter
-----------------------------------------------------------------------

- Net product revenue for ZORYVE was $3.0M in Q4 2022, first full quarter since August 2022 launch.
- Net loss of $72.0M ($1.18/share) in Q4 2022 vs $71.3M ($1.42/share) in Q4 2021.
- Full-year 2022 net loss $311.5M ($5.66/share) vs $206.4M ($4.18/share) in 2021.
- Cash, equivalents, and marketable securities $410.8M as of Dec 31, 2022.
- Positive Phase 3 atopic dermatitis results; NDA submitted for roflumilast foam in seborrheic dermatitis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/0001787306-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787306/000178730623000022/arqt-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001787306-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer